Abstract: Revumenib (SNDX-5613) is a first-in-class, orally bioavailable small-molecule menin inhibitor recently approved for the treatment of relapsed or refractory (R/R) acute leukemias harboring KMT2A rearrangements (KMT2Ar) or NPM1 mutations (NPM1m). By disrupting the menin-KMT2A interaction, revumenib downregulates the leukemogenic HOXA/MEIS1 transcriptional program, thereby relieving the differentiation block and inducing apoptosis in leukemic blasts. While revumenib monotherapy has demonstrated significant efficacy, the emergence of acquired resistance via MEN1 mutations and the clinical need for deeper, more durable remissions have driven research toward combination targeted therapies. This review explores the pharmacological activity, molecular mechanisms, and clinical integration of revumenib in combination with BCL-2 inhibitors, hypomethylating agents, FLT3 inhibitors, and intensive chemotherapy. Furthermore, it addresses current limitations, such as QTc prolongation and differentiation syndrome, and highlights future perspectives in overcoming resistance through rational drug combinations, post-transplant maintenance strategies, and the development of menin degraders.
1. Introduction
Acute myeloid leukemia (AML) is a highly heterogeneous hematologic malignancy characterized by distinct molecular and cytogenetic abnormalities. Among these, KMT2A rearrangements (KMT2Ar) and nucleophosmin 1 (NPM1) mutations account for approximately 5-10% and 30% of AML cases, respectively [4]. Despite their genetic differences, both subsets share a common pathogenetic mechanism: the aberrant activation of the MEIS1-HOXA transcriptional axis, which is strictly dependent on the interaction between the menin scaffold protein and KMT2A [4]. Historically, these leukemias, particularly KMT2Ar AML, have been associated with a dismal prognosis, with a median overall survival (OS) of 2.4 months and a complete remission (CR) rate of only 5% in the relapsed/refractory (R/R) setting [4]. Revumenib (SNDX-5613) is a potent, selective, orally administered menin inhibitor that recently received FDA approval (in late 2024) for adult and pediatric patients with R/R KMT2Ar and NPM1m acute leukemias [6] [11]. While revumenib monotherapy has shown remarkable efficacy, the focus of clinical development has rapidly shifted toward combination targeted therapies to enhance antileukemic activity, overcome resistance mechanisms, and integrate the agent into frontline treatment algorithms [11].
2. Pharmacological Activity
Revumenib has demonstrated robust clinical activity in the pivotal AUGMENT-101 phase 1/2 trial as a monotherapy, achieving an overall response rate (ORR) of 63-64% and a composite complete remission (CRc) rate of 23% in heavily pretreated KMT2Ar and NPM1m patients [11]. To build upon this, revumenib is being extensively evaluated in combination regimens. In the SAVE trial, an all-oral triplet combination of revumenib, decitabine/cedazuridine (ASTX727), and venetoclax in R/R AML yielded an ORR of 82% and a CR/CRh rate of 48%, with 88% of responders achieving measurable residual disease (MRD) negativity [8]. Similarly, the BEAT AML trial investigated revumenib combined with azacitidine and venetoclax in newly diagnosed older adults, reporting an ORR of 88.4% and a CR rate of 67.4%, with 100% of evaluated patients achieving MRD negativity [8]. Furthermore, the AUGMENT-102 trial evaluated revumenib with fludarabine and cytarabine (FLA) chemotherapy, showing a CRc of 50% at the recommended phase 2 dose, with 92% MRD negativity [9]. These combinations demonstrate that revumenib can safely and synergistically enhance the efficacy of standard-of-care regimens, providing deep and durable responses that can bridge patients to potentially curative allogeneic hematopoietic stem cell transplantation (allo-HSCT) [11].
3. Molecular Mechanism of Action
Revumenib functions by selectively binding to the menin protein, thereby disrupting its interaction with KMT2A (both wild-type and fusion proteins) [12]. This disruption dismantles the menin-KMT2A chromatin remodeling complex, leading to the rapid downregulation of leukemogenic target genes, most notably HOXA9 and MEIS1 [12]. Consequently, the leukemic differentiation block is relieved, inducing terminal differentiation and apoptosis of the blasts [12]. In the context of combination therapy, revumenib exhibits profound mechanistic synergy with BCL-2 inhibitors like venetoclax. Menin inhibition downregulates the anti-apoptotic protein MCL-1 and upregulates the pro-apoptotic protein BAX, thereby sensitizing leukemic cells to BCL-2 inhibition and overcoming venetoclax resistance mediated by HOX/MEIS1 upregulation [11]. Additionally, revumenib synergizes with FLT3 inhibitors; the inhibition of the menin-KMT2A complex reduces MEIS1 expression, which subsequently downregulates FLT3 transcription, enhancing the suppression of downstream STAT5A signaling when combined with FLT3 kinase inhibitors [12] [13].
4. Structure-Activity Relationship (SAR)
Revumenib (SNDX-5613) is a close structural analog of the preclinical compound VTP-50469 [10]. It is a small molecule designed to fit precisely into the KMT2A-binding pocket on the menin protein, acting as a competitive inhibitor [10]. Unlike some other menin-targeting agents in development that induce the proteasomal degradation of the menin protein, revumenib functions purely through competitive displacement without degrading menin [10]. Pharmacokinetically, revumenib is a major substrate of the CYP3A4 enzyme. Clinical trials have required split-dose escalation designs to account for the co-administration of strong CYP3A4 inhibitors (such as azole antifungals), which significantly alter its metabolism and require dose adjustments (e.g., 163 mg vs. 113 mg every 12 hours) to maintain optimal therapeutic exposure [12].
5. Current Limitations
The clinical application of revumenib is constrained by specific toxicities and the emergence of resistance. The primary dose-limiting toxicity is asymptomatic QTc prolongation, occurring in up to 40-50% of patients (with grade 3 events in 13-20%), necessitating strict electrocardiogram monitoring and dose modifications [8] [11]. Differentiation syndrome (DS) is another on-target adverse event, reported in 15-20% of patients, which can manifest as leukocytosis, hypoxia, and pulmonary infiltrates, requiring prompt management with corticosteroids and hydroxyurea [8]. Cytopenias, including febrile neutropenia and thrombocytopenia, are also common, particularly in combination regimens [8]. Therapeutically, acquired resistance is a major limitation. Somatic mutations in the MEN1 gene (e.g., at the drug-binding interface) can emerge as early as two cycles into treatment [8]. These mutations disrupt revumenib binding while preserving the oncogenic menin-KMT2A interaction, leading to clinical relapse [8]. Furthermore, co-mutations in TP53 or RAS pathway genes can reduce the overall efficacy of menin inhibitors and are associated with worse survival outcomes [8].
6. Future Perspectives
To overcome resistance and improve long-term survival, the future of revumenib lies in rational combination strategies and expanded clinical indications. Triplet combinations, such as revumenib with hypomethylating agents (azacitidine) and venetoclax, are moving into frontline settings for older, unfit patients to achieve deeper MRD-negative remissions and prevent the outgrowth of MEN1-mutant clones [11]. Combinations with FLT3 inhibitors (e.g., gilteritinib) are being explored for patients with concurrent FLT3 mutations [11]. Additionally, revumenib is being investigated as a post-allo-HSCT maintenance therapy to prevent relapse in high-risk patients, with early data showing sustained MRD-negative remissions [8] [11]. Preclinical research is also exploring synergies with CDK4/6, CDK9, and IDH inhibitors [11]. Finally, the development of menin degraders (PROTACs) represents a promising future direction to overcome resistance caused by binding-site mutations, as degrading the protein entirely could bypass these structural alterations [8].
